Stocksigma LogoStocksigma Logo

Strides Pharma Reports Q2FY27 Results with Ex-US Revenue Surpassing US Business

Strides Pharma Science posted Q2FY27 revenue of ₹14,297m, up 17.1% YoY, driven by Ex-US markets growing 31% YoY to ₹6,963m and surpassing US revenue

Strides Pharma Reports Q2FY27 Results with Ex-US Revenue Surpassing US Business

Strides Pharma Science Ltd · Investor Presentation · 30 Oct 2026, 12:27 am

Strides Pharma Reports Q2FY27 Results with Ex-US Revenue Surpassing US Business Strides Pharma Science posted Q2FY27 revenue of ₹14,297m, up 17.1% YoY, driven by Ex-US markets growing 31% YoY to ₹6,963m and surpassing US revenue (₹6,855m, up 9% YoY) for the first time. EBITDA rose 8.4% YoY to ₹2,509m with margins at 17.6% (-140 bps YoY) due to higher material and logistics costs. Operational PAT grew 11.5% YoY to ₹1,358m. Net debt increased by ₹2,114m in H1FY27 to ₹16,479m (1.72x EBITDA). Strides shifted its ~$375m US revenue goal beyond FY28 amid normalized oral solid opportunities and controlled substance quota constraints.

Original exchange filing (PDF)

More announcements from Strides Pharma Science Ltd

All Strides Pharma Science Ltd announcements